Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Acquires 156,091 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc acquired 156,091 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was acquired at an average price of $7.31 per share, for a total transaction of $1,141,025.21. Following the acquisition, the director owned 5,220,762 shares of the company’s stock, valued at approximately $38,163,770.22. This trade represents a 3.08% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, November 4th, Orbimed Advisors Llc bought 71,367 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc bought 245,113 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The shares were acquired at an average price of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Trading Down 7.8%

ETRA stock opened at $7.35 on Friday. Electra Therapeutics, Inc. has a 52-week low of $6.86 and a 52-week high of $15.50.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ETRA shares. Cantor Fitzgerald assumed coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating for the company. JPMorgan Chase & Co. started coverage on Electra Therapeutics in a report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 target price on the stock. Jefferies Financial Group initiated coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $32.00 target price on the stock. HC Wainwright began coverage on Electra Therapeutics in a report on Monday, October 26th. They set a “buy” rating and a $30.00 price target for the company. Finally, TD Cowen began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Electra Therapeutics has an average rating of “Buy” and a consensus target price of $33.50.

Key Headlines Impacting Electra Therapeutics

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, associated with OrbiMed Advisors, reported purchases totaling 472,571 shares across November 3–5, worth approximately $3.6 million. The transactions increased his reported position, a sign of insider confidence. SEC filing
• Neutral Sentiment: Management plans to present at the Jefferies Global Healthcare Conference in London on November 18. The announcement provides an opportunity to discuss the company, but no new clinical or business developments were included. Conference announcement

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.